200 likes | 208 Views
The global viral vector and plasmid manufacturing market was estimated to reach $5.86 billion in 2030 , growing at a significant CAGR of 16.28% during the forecast period from 2020 to 2030.
E N D
Global Viral Vector and Plasmid Manufacturing Market Focus on Vector Type, Application, Disease, 5 Region’s Data, 15 Countries’ Data, Patent Landscape and Competitive Insights Analysis and Forecast: 2020-2030 May 2020 TOC
Global Viral Vector and Plasmid Manufacturing Market BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2020 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by, or offered whether for sale or otherwise to any third party. All rights reserved at BIS Research 2
Global Viral Vector and Plasmid Manufacturing Market T Table of able of C Contents ontents Executive Summary……………………………………………...……….…….20 1. Product Definition .............................................................................................. 35 2. Scope of the Work .............................................................................................. 36 2.1 2.2 Overview: Report Scope .............................................................................. 36 Segmentation of the Global Viral Vector and Plasmid Manufacturing Market .................................................................................. 37 Assumptions and Limitations ..................................................................... 38 Key Questions Answered in the Report ..................................................... 39 Base Year and Forecast Period .................................................................. 40 2.3 2.4 2.5 3. Research Methodology ...................................................................................... 41 3.1 Overview: Report Methodology .................................................................. 41 4. Global Viral Vector and Plasmid Manufacturing Market Overview ................ 48 4.1 4.2 4.3 4.4 Market Overview ........................................................................................... 48 Introduction to Vectors ................................................................................ 49 Importance of Viral Vectors and Plasmid DNA .......................................... 50 Major Milestone in Vector Manufacturing .................................................. 53 4.4.1 Manufacturing Process ..................................................................... 53 4.4.1.1 Upstream Bioprocessing ..................................................................... 53 4.4.1.2 Downstream Bioprocessing ................................................................. 54 4.5 Global Viral Vector and Plasmid Manufacturing Market Size, 2019- 2030 ............................................................................................................... 55 5. Market Dynamics ................................................................................................ 56 5.1 Market Drivers .............................................................................................. 57 5.1.1 Rapid Uptake of Viral Vectors and Plasmid for the Development of Innovative Therapies ............................................. 57 5.1.2 Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases ........................................................................... 59 5.1.3 Increasing Number of Clinical Studies for the Development of Gene Therapy ................................................................................ 61 All rights reserved at BIS Research 3
Global Viral Vector and Plasmid Manufacturing Market Favorable Funding Scenario for Vector-Based Therapies ............. 63 Market Restraints ......................................................................................... 64 5.2.1 Unaffordable Cost of Gene Therapies ............................................. 64 5.2.2 High Manufacturing Costs of Viral Vectors and Plasmids ............. 66 5.2.3 Complications Associated With Large-Scale Production of Vectors ............................................................................................... 66 5.3 Market Opportunities ................................................................................... 67 5.3.1 Rising Demand for Synthetic Genes ................................................ 67 5.3.2 Emergence of Next-Generation Vectors .......................................... 68 5.1.4 5.2 6. Industry Insights ................................................................................................. 69 6.1 6.2 6.3 Overview ....................................................................................................... 69 Regulatory Scenario .................................................................................... 71 Patent Landscape ........................................................................................ 75 7. Competitive Landscape ..................................................................................... 80 7.1 7.2 Overview ....................................................................................................... 80 Key Developments and Strategies ............................................................. 81 7.2.1 Partnerships and Alliances .............................................................. 82 7.2.2 Business Expansions ....................................................................... 84 7.2.3 New Offerings .................................................................................... 86 7.2.4 M & A Activities ................................................................................. 87 7.2.5 Others ................................................................................................. 89 7.3 Market Share Analysis ................................................................................. 90 8. Global Viral Vector and Plasmid Manufacturing Market (by Vector) .............. 92 8.1 8.2 Overview ....................................................................................................... 92 Viral Vector ................................................................................................... 95 8.2.1 Adenoviral Vector .............................................................................. 99 8.2.2 Retroviral Vector .............................................................................. 101 8.2.3 Adeno-Associated Viral Vector ...................................................... 103 8.2.4 Lentiviral Vector .............................................................................. 105 8.2.5 Vaccinia Viral Vector ....................................................................... 107 8.2.6 Other Viral Vectors .......................................................................... 108 All rights reserved at BIS Research 4
Global Viral Vector and Plasmid Manufacturing Market 8.3 Plasmid ....................................................................................................... 110 9. Global Viral Vector and Plasmid Manufacturing Market (by Disease) ......... 113 9.1 9.2 9.3 9.4 9.5 9.6 Overview ..................................................................................................... 113 Cancer ......................................................................................................... 116 Genetic Disease ......................................................................................... 119 Infectious Disease ...................................................................................... 122 Cardiovascular Disease ............................................................................. 124 Other Diseases ........................................................................................... 126 10. Global Viral Vector and Plasmid Manufacturing Market (by Application) ... 128 10.1Overview ..................................................................................................... 128 10.2Gene Therapy ............................................................................................. 131 10.3Vaccinology ................................................................................................ 135 10.4Cell Therapy ................................................................................................ 138 10.5Other Applications ..................................................................................... 139 11. Global Viral Vector and Plasmid Manufacturing Market (by Region) ........... 142 11.1Overview ..................................................................................................... 142 11.2North America ............................................................................................ 145 11.2.1 Overview .......................................................................................... 145 11.2.2 U.S. ................................................................................................... 149 11.2.3 Canada ............................................................................................. 152 11.3Europe ......................................................................................................... 154 11.3.1 Overview .......................................................................................... 154 11.3.2 Germany ........................................................................................... 158 11.3.3 U.K. ................................................................................................... 159 11.3.4 France ............................................................................................... 161 11.3.5 Italy ................................................................................................... 162 11.3.6 Switzerland ...................................................................................... 164 11.3.7 Belgium ............................................................................................ 165 11.3.8 Spain ................................................................................................. 167 11.3.9 Rest-of-Europe................................................................................. 169 11.4Asia-Pacific ................................................................................................. 170 All rights reserved at BIS Research 5
Global Viral Vector and Plasmid Manufacturing Market 11.4.1 11.4.2 11.4.3 11.4.4 11.4.5 11.4.6 11.4.7 11.4.8 11.5Rest-of-the-World ....................................................................................... 184 11.5.1 Overview .......................................................................................... 184 Overview .......................................................................................... 170 China ................................................................................................ 174 Australia ........................................................................................... 176 Japan ................................................................................................ 177 India .................................................................................................. 179 South Korea ..................................................................................... 181 Singapore ......................................................................................... 182 Rest-of-Asia-Pacific ......................................................................... 183 12. Company Profiles ............................................................................................. 188 12.1Overview ..................................................................................................... 188 12.2Aldevron, LLC ............................................................................................. 189 12.2.1 Company Overview ......................................................................... 189 12.2.2 Role of Aldevron, LLC in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 189 12.2.3 SWOT Analysis ................................................................................ 192 12.3Boehringer Ingelheim ................................................................................ 193 12.3.1 Company Overview ......................................................................... 193 12.3.2 Role of Boehringer Ingelheim in the Global Viral Vector and Plasmid Manufacturing Market ...................................................... 193 12.3.3 SWOT Analysis ................................................................................ 195 12.4Catalent, Inc. ............................................................................................... 196 12.4.1 Company Overview ......................................................................... 196 12.4.2 Role of Catalent, Inc. in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 196 12.4.3 Financials ......................................................................................... 198 12.4.4 Key Insights About Financial Health of the Company ................. 200 12.4.5 SWOT Analysis ................................................................................ 202 12.5FUJIFILM Holdings Corporation ............................................................... 203 12.5.1 Company Overview ......................................................................... 203 12.5.2 Role of FUJIFILM Holdings Corporation in the Global Viral Vector and Plasmid Manufacturing Market ................................... 203 All rights reserved at BIS Research 6
Global Viral Vector and Plasmid Manufacturing Market 12.5.3 12.5.4 12.5.5 12.6GENERAL ELECTRIC ................................................................................. 210 12.6.1 Company Overview ......................................................................... 210 12.6.2 Role of GENERAL ELECTRIC in the Global Viral Vector and Plasmid Manufacturing Market ...................................................... 210 12.6.3 Financials ......................................................................................... 212 12.6.4 Key Insights About Financial Health of the Company ................. 215 12.6.5 SWOT Analysis ................................................................................ 216 12.7GenScript .................................................................................................... 217 12.7.1 Company Overview ......................................................................... 217 12.7.2 Role of GenScript in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 217 12.7.3 Financials ......................................................................................... 218 12.7.4 Key Insights About Financial Health of the Company ................. 219 12.7.5 SWOT Analysis ................................................................................ 220 12.8Lonza ........................................................................................................... 221 12.8.1 Company Overview ......................................................................... 221 12.8.2 Role of Lonza in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 221 12.8.3 Financials ......................................................................................... 223 12.8.4 Key Insights About Financial Health of the Company ................. 226 12.8.5 SWOT Analysis ................................................................................ 227 12.9Merck KGaA ................................................................................................ 228 12.9.1 Company Overview ......................................................................... 228 12.9.2 Role of Merck KGaA in the Global Viral Vector and Plasmid Market ............................................................................................... 228 12.9.3 Financials ......................................................................................... 230 12.9.4 Key Insights About Financial Health of the Company ................. 233 12.9.5 SWOT Analysis ................................................................................ 234 12.10MolMed S.p.A. ............................................................................................. 235 12.10.1 Company Overview ......................................................................... 235 Financials ......................................................................................... 205 Key Insights About Financial Health of the Company ................. 207 SWOT Analysis ................................................................................ 209 All rights reserved at BIS Research 7
Global Viral Vector and Plasmid Manufacturing Market Role of MolMed S.p.A. in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 235 Financials ......................................................................................... 237 SWOT Analysis ................................................................................ 238 12.11Novasep Holding SAS................................................................................ 239 12.11.1 Company Overview ......................................................................... 239 12.11.2 Role of Novasep Holding SAS in the Global Viral Vector and Plasmid Manufacturing Market ...................................................... 239 12.11.3 SWOT Analysis ................................................................................ 241 12.12Oxford Biomedica plc ................................................................................ 242 12.12.1 Company Overview ......................................................................... 242 12.12.2 Role of Oxford Biomedica plc in the Global Viral Vector and Plasmid Manufacturing Market ...................................................... 242 12.12.3 Financials ......................................................................................... 244 12.12.4 Key Insights About Financial Health of the Company ................. 246 12.12.5 SWOT Analysis ................................................................................ 247 12.13Sartorius AG ............................................................................................... 248 12.13.1 Company Overview ......................................................................... 248 12.13.2 Role of Sartorius AG in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 248 12.13.3 Financials ......................................................................................... 250 12.13.4 Key Insights About Financial Health of the Company ................. 252 12.13.5 SWOT Analysis ................................................................................ 253 12.14Takara Bio Inc. ............................................................................................ 254 12.14.1 Company Overview ......................................................................... 254 12.14.2 Role of Takara Bio Inc. in the Global Viral Vector and Plasmid Manufacturing Market ...................................................... 254 12.14.3 Financials ......................................................................................... 256 12.14.4 Key Insights About Financial Health of the Company ................. 258 12.14.5 SWOT Analysis ................................................................................ 259 12.15Thermo Fisher Scientific Inc. .................................................................... 260 12.15.1 Company Overview ......................................................................... 260 12.15.2 Role of Thermo Fisher Scientific Inc. in the Global Viral Vector and Plasmid Manufacturing Market ................................... 260 12.10.2 12.10.3 12.10.4 All rights reserved at BIS Research 8
Global Viral Vector and Plasmid Manufacturing Market 12.15.3 12.15.4 12.15.5 12.16WuXi AppTec .............................................................................................. 266 12.16.1 Company Overview ......................................................................... 266 12.16.2 Role of WuXi AppTec in the Global Viral Vector and Plasmid Manufacturing Market ..................................................................... 266 12.16.3 Financials ......................................................................................... 268 12.16.4 Key Insights About Financial Health of the Company ................. 271 12.16.5 SWOT Analysis: WuXi AppTec ....................................................... 272 Financials ......................................................................................... 262 Key Insights About Financial Health of the Company ................. 264 SWOT Analysis ................................................................................ 265 All rights reserved at BIS Research 9
Global Viral Vector and Plasmid Manufacturing Market List of Tables List of Tables Table 1: Leading Segments of the Global Viral Vector and Plasmid Manufacturing Market, 2019 and 2030 ......................................................................................................................... 25 Table 4.1: Advantages and Disadvantages of Common Viral Vectors and Plasmids ....................... 51 Table 5.1: Gene Therapy for Different Types of Cancer ..................................................................... 60 Table 5.2: Recent Approvals for Gene Therapy .................................................................................. 62 Table 5.3: Companies Offering Gene Therapies and Their Cost ....................................................... 65 Table 6.1: Global Regulatory Scenario ................................................................................................ 72 Table 6.2: Patents Related to Viral Vectors and Plasmids (January 2017-February 2020) ............. 76 Table 8.1: Examples of Viral Vectors Used in Gene Therapy ............................................................ 96 Table 8.2: Plasmids Used in Gene Therapy Trials ............................................................................ 111 Table 9.1: Examples of Ad Vectors for Cancer Gene Therapy ........................................................ 116 Table 9.2: Features of Vectors Used in Cardiovascular Therapy ..................................................... 124 Table 10.1: Examples of Clinical Trials Using Viral Vectors ............................................................. 132 Table 10.2: Advantages and Disadvantages Associated with Major Viral Vectors ......................... 135 Table 11.1: Examples of Key Companies with Headquarters in the U.S. ........................................ 151 All rights reserved at BIS Research 10
Global Viral Vector and Plasmid Manufacturing Market List of List of Figures Figures Figure 1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030 ......................................................................................................................... 23 Figure 2: Key Players of the Global Viral Vector and Plasmid Manufacturing Market ....................... 24 Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................................. 27 Figure 4: Share of Key Developments and Strategies, January 2017-February 2020 ...................... 28 Figure 5: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030 ......................................................................................................................... 29 Figure 6: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030 ......................................................................................................................... 30 Figure 7: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030 ......................................................................................................................... 31 Figure 8: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030 ......................................................................................................................... 33 Figure 2.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation ........................... 37 Figure 3.1: Global Viral Vector and Plasmid Manufacturing Market Research Methodology ........... 42 Figure 3.2: Primary Research .............................................................................................................. 43 Figure 3.3: Secondary Research ......................................................................................................... 44 Figure 3.4: Data Triangulation .............................................................................................................. 45 Figure 3.5: Bottom-up Approach (Segment-Wise Analysis) ............................................................... 46 Figure 3.6: Top-Down Approach (Segment-Wise Analysis) ............................................................... 46 Figure 3.7: Assumptions and Limitations ............................................................................................. 47 The following figure demonstrates the procedure of application of vectors as a therapeutic tool, starting from the identification of the infected cell to the final integration of the gene of interest......................................................................................................................... 52 Figure 4.1: Mechanism of Action of Vectors ........................................................................................ 52 Figure 4.2: Evolutionary History of Vectors ......................................................................................... 53 Figure 4.3: Typical Production Methods of Viral Vectors and Plasmids ............................................. 54 Figure 4.4: Global Viral Vector and Plasmid Manufacturing Market, 2019-2030 ............................... 55 All rights reserved at BIS Research 11
Global Viral Vector and Plasmid Manufacturing Market Figure 5.1: Drivers, Challenges, and Opportunities of the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................................. 57 Figure 5.2: Estimated New Cancer Cases and Deaths (by Sex), U.S., 2020 .................................... 59 Figure 6.1: Workflow Associated With Biomanufacturing ................................................................... 70 Figure 6.2: Global Viral Vector and Plasmid Manufacturing Market: Patent Analysis (by Year of Publication), June 2017-December 2019 ........................................................................... 79 Figure 7.1: Competitive Landscape, January 2017- March 2020 ....................................................... 81 Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020 ................... 82 Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020 ...................... 83 Figure 7.4: Business Expansions (by Company), January 2017-February 2020 .............................. 85 Figure 7.5: New Offerings (by Company), January 2017-February 2020 .......................................... 86 Figure 7.6: M&A Activities (by Company), January 2017-February 2020 .......................................... 88 Figure 7.7: Others (by Company), January 2017-February 2020 ...................................................... 89 Figure 7.8: Market Share Analysis of Global Viral Vector and Plasmid Manufacturing Market, 2019 ............................................................................................................................ 91 Figure 8.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Vector) ................................................................................................................................ 93 Figure 8.2: Global Viral Vector and Plasmid Manufacturing Market (by Vector Type), 2019 and 2030 ......................................................................................................................... 94 Figure 8.3: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030 ................................................................................................................................ 97 Figure 8.4: Global Viral Vector and Plasmid Manufacturing Market (by Viral Vector), 2019 and 2030 ......................................................................................................................... 98 Figure 8.5: Global Viral Vector and Plasmid Manufacturing Market for Adenoviral Vectors, 2019-2030 .............................................................................................................................. 100 Figure 8.6: Global Viral Vector and Plasmid Manufacturing Market for Retroviral Vectors, 2019-2030 .............................................................................................................................. 102 Figure 8.7: Global Viral Vector and Plasmid Manufacturing Market for Adeno-Associated Viral Vectors, 2019-2030 ....................................................................................................... 104 Figure 8.8: Global Viral Vector and Plasmid Manufacturing Market for Lentiviral Vectors, 2019-2030 .............................................................................................................................. 106 All rights reserved at BIS Research 12
Global Viral Vector and Plasmid Manufacturing Market Figure 8.9: Global Viral Vector and Plasmid Manufacturing Market for Vaccinia Viral Vectors, 2019-2030 .............................................................................................................................. 108 Figure 8.10: Global Viral Vector and Plasmid Manufacturing Market for Other Viral Vectors, 2019-2030 .............................................................................................................................. 109 Figure 8.11: Global Viral Vector and Plasmid Manufacturing Market for Viral Vectors, 2019-2030 .............................................................................................................................. 112 Figure 9.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Disease) ................................................................................................................................. 114 Figure 9.2: Global Viral Vector and Plasmid Manufacturing Market (by Disease), 2019 and 2030 ....................................................................................................................... 115 Figure 9.3: Global Viral Vector and Plasmid Manufacturing Market for Cancer, 2019-2030 .......... 119 Figure 9.4: List of Monogenic Disorders for which Human Gene Transfer Trials Have Been Approved ...................................................................................................................... 120 Figure 9.5: Global Viral Vector and Plasmid Manufacturing Market for Genetic Diseases, 2019-2030 .............................................................................................................................. 121 Figure 9.6: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030 .............................................................................................................................. 123 Figure 9.7: Global Viral Vector and Plasmid Manufacturing Market for Infectious Diseases, 2019-2030 .............................................................................................................................. 125 Figure 9.8: Global Viral Vector and Plasmid Manufacturing Market for Other Diseases, 2019-2030 .............................................................................................................................. 127 Figure 10.1: Global Viral Vector and Plasmid Manufacturing Market Segmentation (by Application) ............................................................................................................................. 129 Figure 10.2: Global Viral Vector and Plasmid Manufacturing Market (by Application), 2019 and 2030 ................................................................................................................................ 130 Figure 10.3: Global Viral Vector and Plasmid Manufacturing Market for Gene Therapy, 2019-2030 .............................................................................................................................. 134 Figure 10.4: Global Viral Vector and Plasmid Manufacturing Market for Vaccinology, 2019-2030 .............................................................................................................................. 137 Figure 10.5: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030 .............................................................................................................................. 139 All rights reserved at BIS Research 13
Global Viral Vector and Plasmid Manufacturing Market Figure 10.6: Global Viral Vector and Plasmid Manufacturing Market for Cell Therapy, 2019-2030 .............................................................................................................................. 140 Figure 11.1: Global Viral Vector and Plasmid Manufacturing Market (by Region), 2019 and 2030 ....................................................................................................................... 144 Figure 11.2: North America: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ............. 146 Figure 11.3: North America: Market Dynamics ................................................................................. 147 Figure 11.4: North America: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030 ....................................................................................................................... 148 Figure 11.5: U.S.: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ............................. 150 Figure 11.6: Canada: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ....................... 153 Figure 11.7: Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ........................ 155 Figure 11.8: Europe: Market Dynamics ............................................................................................. 156 Figure 11.9: Europe: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030 ....................................................................................................................... 157 Figure 11.10: Germany: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ................... 159 Figure 11.11: U.K.: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ........................... 160 Figure 11.12: France: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ....................... 162 Figure 11.13: Italy: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ............................ 163 Figure 11.14: Switzerland: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ............... 165 Figure 11.15: Belgium: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ..................... 166 Figure 11.16: Spain: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ......................... 168 Figure 11.17: Rest-of-Europe: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ......... 169 Figure 11.18: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ............... 171 Figure 11.19: Asia-Pacific: Market Dynamics .................................................................................... 172 Figure 11.20: Asia-Pacific: Viral Vector and Plasmid Manufacturing Market (by Country), 2019 and 2030 ....................................................................................................................... 173 Figure 11.21: China: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ......................... 175 Figure 11.22: Australia: Viral Vector and Plasmid Manufacturing Market, 2019-2030 .................... 177 Figure 11.23: Japan: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ........................ 178 Figure 11.24: India: Viral Vector and Plasmid Manufacturing Market, 2019-2030 .......................... 180 Figure 11.25: South Korea: Viral Vector and Plasmid Manufacturing Market, 2019-2030 .............. 181 Figure 11.26: Singapore: Viral Vector and Plasmid Manufacturing Market, 2019-2030 ................. 183 All rights reserved at BIS Research 14
Global Viral Vector and Plasmid Manufacturing Market Figure 11.27: Rest-of-Asia-Pacific: Viral Vector and Plasmid Manufacturing Market, 2019-2030 .............................................................................................................................. 184 Figure 11.28: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market, 2019-2030 .............................................................................................................................. 185 Figure 11.29: Rest-of-the-World: Viral Vector and Plasmid Manufacturing Market (Latin America and Middle-East and Africa), 2019-2030 ................................................................ 186 Figure 12.1: Shares of Key Company Profiles .................................................................................. 188 Figure 12.2: Aldevron, LLC: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market ............................................................................................................ 190 Figure 12.3: Aldevron, LLC: SWOT Analysis .................................................................................... 192 Figure 12.4: Boehringer Ingelheim: Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market ............................................................................................................ 194 Figure 12.5: Boehringer Ingelheim: SWOT Analysis ........................................................................ 195 Figure 12.6: Catalent, Inc: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market ............................................................................................................ 197 Figure 12.7: Catalent, Inc: Overall Financials, 2017-2019 ................................................................ 198 Figure 12.8: Catalent, Inc.: Net Revenue (by Business Segment), 2017-2019 ............................... 199 Figure 12.9: Catalent, Inc.: Net Revenue (by Region), 2017-2019 .................................................. 200 Figure 12.10: Catalent, Inc.: R&D Expense, 2017-2019 ................................................................... 201 Figure 12.11: Catalent, Inc.: SWOT Analysis .................................................................................... 202 Figure 12.12: FUJIFILM Holdings Corporation: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market ........................................................................... 204 Figure 12.13: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019 .............................. 205 Figure 12.14: FUJIFILM Holdings Corporation: Net Revenue (by Business Segment), 2017-2019 .............................................................................................................................. 206 Figure 12.15: FUJIFILM Holdings Corporation: Healthcare and Material Solutions Revenue (by Sub-Segment), 2017-2019 .............................................................................................. 207 Figure 12.16: FUJIFILM Holdings Corporation: R&D Expense, 2017-2019 .................................... 208 Figure 12.17: FUJIFILM Holdings Corporation: SWOT Analysis ..................................................... 209 Figure 12.18: GE Healthcare: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................. 211 Figure 12.19: GENERAL ELECTRIC Company: Overall Financials, 2017-2019 ............................ 212 All rights reserved at BIS Research 15
Global Viral Vector and Plasmid Manufacturing Market Figure 12.20: GENERAL ELECTERIC: Revenue (by Business Model), 2017-2019 ...................... 213 Figure 12.21: GENERAL ELECTRIC: Revenue (by Region), 2017-2019 ....................................... 214 Figure 12.22: GENERAL ELECTRIC: R&D Expenditure, 2017-2019 .............................................. 215 Figure 12.23: GENERAL ELECTRIC: SWOT Analysis .................................................................... 216 Figure 12.24: GenScript: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market ............................................................................................................ 218 Figure 12.25: GenScript: Overall Financials, 2016-2018 .................................................................. 218 Figure 12.26: GenScript: R&D Expense, 2016-2018 ........................................................................ 219 Figure 12.27: GenScript: SWOT Analysis ......................................................................................... 220 Figure 12.28: Lonza: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market ............................................................................................................ 222 Figure 12.29: Lonza: Overall Financials, 2017-2019 ........................................................................ 223 Figure 12.30: Lonza: Revenue (by Segment), 2017-2019 ............................................................... 224 Figure 12.31: Lonza: Revenue (by Region), 2017-2019 ................................................................... 225 Figure 12.32: Lonza: R&D Expenditure (2017-2019) ........................................................................ 226 Figure 12.33: Lonza: SWOT Analysis ............................................................................................... 227 Figure 12.35: Merck KGaA: Overall Financials, 2017-2019 ............................................................. 230 Figure 12.36: Merck KGaA: Revenue (by Product and Services), 2017-2019 ................................ 231 Figure 12.37: Merck KGaA: Revenue (by Region), 2017-2019 ........................................................ 232 Figure 12.38: Merck KGaA: R&D Expenditure, 2017-2019 .............................................................. 233 Figure 12.40: MolMed S.p.A.: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................. 236 Figure 12.41: MolMed S.p.A.: Overall Financials, 2016-2018 .......................................................... 237 Figure 12.42: MolMed S.p.A.: SWOT Analysis ................................................................................. 238 Figure 12.43: Novasep Holding SAS: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market ....................................................................................... 240 Figure 12.44: Novasep Holding SAS: SWOT Analysis ..................................................................... 241 Figure 12.45: Oxford Biomedica plc: Service / Product Portfolio for Global Viral Vector and Plasmid Manufacturing Market .............................................................................................. 243 Figure 12.46: Oxford Biomedica plc: Overall Financials, 2016-2018 ............................................... 244 Figure 12.47: Oxford Biomedica plc: Revenue (by Segment), 2016-2018 ...................................... 245 Figure 12.48: Oxford Biomedica plc: R&D Expenditure (2016-2018) .............................................. 246 All rights reserved at BIS Research 16
Global Viral Vector and Plasmid Manufacturing Market Figure 12.49: Oxford Biomedica plc: SWOT Analysis ...................................................................... 247 Figure 12.50: Sartorius AG: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................. 249 Figure 12.51: Sartorius AG: Overall Financials, 2017-2019 ............................................................. 250 Figure 12.52: Sartorius AG: Revenue (by Business Segment), 2017-2019 .................................... 251 Figure 12.53: Sartorius AG: Revenue (by Region), 2017-2019........................................................ 252 Figure 12.54: Sartorius AG: R&D Expenditure (2017-2019) ............................................................ 252 Figure 12.55: Sartorius AG: SWOT Analysis .................................................................................... 253 Figure 12.56: Takara Bio Inc.: Service/Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................. 255 Figure 12.57: Takara Bio Inc.: Overall Financials, 2017-2019.......................................................... 256 Figure 12.58: Takara Bio Inc.: Revenue (by Business Segment), 2017-2019 ................................. 257 Figure 12.59: Takara Bio Inc.: Revenue (by Region), 2017-2019 .................................................... 258 Figure 12.60: Takara Bio Inc.: R&D Expenditure (2017-2019) ......................................................... 258 Figure 12.61: Takara Bio Inc.: SWOT Analysis ................................................................................. 259 Figure 12.62: Thermo Fisher Scientific, Inc.: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market ........................................................................... 261 Figure 12.63: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019 ................................... 262 Figure 12.64: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2017-2019 .......... 263 Figure 12.65: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2017-2019 ............................. 263 Figure 12.66: Thermo Fisher Scientific, Inc.: R&D Expenditure (2017-2019) .................................. 264 Figure 12.67: Thermo Fisher Scientific, Inc.: SWOT Analysis .......................................................... 265 Figure 12.68: WuXi AppTec: Service / Product Portfolio for the Global Viral Vector and Plasmid Manufacturing Market .............................................................................................. 267 Figure 12.69: WuXi AppTec: Overall Financials, 2016-2018 ............................................................ 268 Figure 12.70: WuXi AppTec: Net Revenue (by Business Segment), 2016-2018 ............................ 269 Figure 12.71: WuXi AppTec: Net Revenue (by Region), 2016-2018 ............................................... 270 Figure 12.72: WuXi AppTec: R&D Expense, 2016-2018 .................................................................. 271 Figure 12.73: WuXi AppTec: SWOT Analysis ................................................................................... 272 All rights reserved at BIS Research 17
Global Viral Vector and Plasmid Manufacturing Market BIS Research Offerings: BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the written consent of BIS Research. The customer will not disclose the contents of the report, whether directly through any medium or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of information to generate any statistical or other information that is or will be provided to third parties, or voluntarily produce information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or Know More Know More Know More businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies Know More All rights reserved at BIS Research 18
Global Viral Vector and Plasmid Manufacturing Market Disclaimer Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the written consent of BIS Research. The customer will not disclose the contents of the report, whether directly through any medium or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of information to generate any statistical or other information that is or will be provided to third parties, or voluntarily produce information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 All rights reserved at BIS Research 19
Global Viral Vector and Plasmid Manufacturing Market BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: info@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 All rights reserved at BIS Research 20